Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 2
2002 1
2004 1
2006 1
2008 1
2009 2
2010 1
2012 1
2014 1
2015 2
2017 2
2019 5
2020 3
2021 3
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA. Liao W, et al. Among authors: maeda dy. Cancer Cell. 2019 Apr 15;35(4):559-572.e7. doi: 10.1016/j.ccell.2019.02.008. Epub 2019 Mar 21. Cancer Cell. 2019. PMID: 30905761 Free PMC article.
Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Lu X, et al. Among authors: maeda dy. Nature. 2017 Mar 30;543(7647):728-732. doi: 10.1038/nature21676. Epub 2017 Mar 20. Nature. 2017. PMID: 28321130 Free PMC article.
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.
Gulhati P, Schalck A, Jiang S, Shang X, Wu CJ, Hou P, Ruiz SH, Soto LS, Parra E, Ying H, Han J, Dey P, Li J, Deng P, Sei E, Maeda DY, Zebala JA, Spring DJ, Kim M, Wang H, Maitra A, Moore D, Clise-Dwyer K, Wang YA, Navin NE, DePinho RA. Gulhati P, et al. Among authors: maeda dy. Nat Cancer. 2023 Jan;4(1):62-80. doi: 10.1038/s43018-022-00500-z. Epub 2022 Dec 30. Nat Cancer. 2023. PMID: 36585453 Free PMC article.
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.
Tang KH, Li S, Khodadadi-Jamayran A, Jen J, Han H, Guidry K, Chen T, Hao Y, Fedele C, Zebala JA, Maeda DY, Christensen JG, Olson P, Athanas A, Loomis CA, Tsirigos A, Wong KK, Neel BG. Tang KH, et al. Among authors: maeda dy. Cancer Discov. 2022 Jan;12(1):47-61. doi: 10.1158/2159-8290.CD-21-0369. Epub 2021 Aug 5. Cancer Discov. 2022. PMID: 34353854 Free PMC article.
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer.
Zhu Y, Zhao Y, Wen J, Liu S, Huang T, Hatial I, Peng X, Al Janabi H, Huang G, Mittlesteadt J, Cheng M, Bhardwaj A, Ashfeld BL, Kao KR, Maeda DY, Dai X, Wiest O, Blagg BSJ, Lu X, Cheng L, Wan J, Lu X. Zhu Y, et al. Among authors: maeda dy. Sci Immunol. 2023 Mar 17;8(81):eade4656. doi: 10.1126/sciimmunol.ade4656. Epub 2023 Mar 10. Sci Immunol. 2023. PMID: 36897957 Free PMC article.
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, Zebala JA, Clavijo PE, Allen C. Greene S, et al. Among authors: maeda dy. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. doi: 10.1158/1078-0432.CCR-19-2625. Epub 2019 Dec 17. Clin Cancer Res. 2020. PMID: 31848188 Free PMC article.
31 results